RSV: 1. Implement a respiratory syncytial virus (RSV) protection strategy that includes the use of Nirsevimab (specific monoclonal antibody) and RSVpreF vaccine in pregnant women between 32 and 36.6 weeks. Use nirsevimab in infants older than 6 months who have risk factors for severe RSV disease in their first RSV season, 3. Consider a booster dose of nirsevimab in their second season of RSV exposure in children older than 6 months up to 2 years of age who have risk factors for severe disease. 4. Adopt a combined strategy due to the limited availability of both biologics in the short and medium term, in line with international recommendations, to sustain the measure over time.